Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock
NATICK, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 397,087 shares of its common stock at a price of $42.50
View HTML
Toggle Summary Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
NATICK, Mass. , June 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 2,647,247 shares of its common stock at a price of $42.50 per share before underwriting discounts.
View HTML
Toggle Summary Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
NATICK, Mass., June 25, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 2,200,000 shares of its common stock. The offering is expected to consist of 2,000,000 shares to be offered by Karyopharm and 200,000
View HTML
Toggle Summary Karyopharm Initiates Registration-Directed, Randomized Study of Selinexor (KPT-330) in Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 "SOPRA" Clinical Trial With Overall Survival Endpoint
View HTML
Toggle Summary Karyopharm Announces: FDA Considers the Effectiveness and Safety Technical Sections Complete to Support Conditional Approval for the New Animal Drug Application for Verdinexor (KPT-335) to Treat Lymphoma in Client Owned Dogs
NATICK, Mass., June 16, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel, first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major
View HTML
Toggle Summary Karyopharm Announces First Combination Data of Selinexor With Low-Dose Dexamethasone in Heavily Pretreated Multiple Myeloma Patients
Six Data Presentations at the European Hematology Association's 19th Congress
View HTML
Toggle Summary Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)
NATICK, Mass. , June 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major
View HTML
Toggle Summary Karyopharm Updates Data for Selinexor in Solid Tumors at 2014 ASCO Annual Meeting
First Presentation of Phase 1 Food Effects Study in Advanced Sarcomas
View HTML
Toggle Summary Karyopharm Provides Data Update for Selinexor in Non-Hodgkin's Lymphoma and Acute Myeloid Leukemia at 2014 ASCO Annual Meeting
NATICK, Mass. , May 31, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with hematologic
View HTML
Toggle Summary Karyopharm to Webcast Investor & Analyst Briefing on Monday, June 2, 2014
Webcast Will Start at 6:15 PM Central Time
View HTML